Opdivo

BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval
Fierce Pharma
Thu, 10/3/24 - 10:25 pm
Bristol Myers Squibb
Opdivo
FDA
non-small cell lung cancer
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Wed, 10/2/24 - 11:24 am
FDA
Bridge Bio
acoramidis
AstraZeneca
Daiichi Sankyo
Dato-DXd
Vertex Pharmaceuticals
Vanza Triple
PTC Therapeutics
Upstaza
Bristol Myers Squibb
Opdivo
FDA weighs limiting PD-1 drugs in stomach cancer, calls on experts to discuss Merck, BMS and BeiGene meds
Fierce Pharma
Fri, 08/23/24 - 10:55 am
FDA
stomach cancer
Bristol Myers Squibb
Opdivo
Yervoy
Merck
Keytruda
BeiGene
Tevimbra
BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer
Pharmaphorum
Thu, 08/22/24 - 11:09 am
Bristol Myers Squibb
Opdivo
Yervoy
liver cancer
FDA
Aveo spins a silver lining in failed trial of kidney cancer drug Fotivda
Fierce Pharma
Thu, 07/18/24 - 11:06 pm
Aveo Oncology
kidney cancer
Fotivda
Opdivo
Bristol Myers Squibb
ASCO: With Opdivo-Yervoy combo, Bristol Myers calls Roche and AstraZeneca's bets in first-line liver cancer
Fierce Pharma
Tue, 06/4/24 - 11:52 am
ASCO 2024
Bristol Myers Squibb
Opdivo
Yervoy
liver cancer
Merck
Eisai
Bayer
Lenvima
Nexavar
Bristol Myers lines up Opdivo treatment in Pakistan, Rwanda and beyond as part of 10-year access campaign
Fierce Pharma
Wed, 05/22/24 - 11:36 am
Bristol Myers Squibb
Opdivo
Pakistan
Rwanda
Zambia
LMICs
FDA Updates PDUFA Date of BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
Onc Live
Tue, 05/21/24 - 07:15 pm
FDA
Bristol Myers Squibb
Opdivo
Halozyme
solid tumors
As Bristol Myers reveals trial failure, AstraZeneca's Imfinzi stays king in stage 3 lung cancer
Fierce Pharma
Mon, 05/13/24 - 11:20 am
Bristol Myers Squibb
Opdivo
Yervoy
clinical trials
non-small cell lung cancer
AstraZeneca
Imfinzi
BMS to cut 2,200 jobs in $1.5B restructuring as Opdivo sales drop in Q1
BioSpace
Thu, 04/25/24 - 11:44 am
Bristol Myers Squibb
earnings
Opdivo
layoffs
5 Successful Phase III Oncology Trials in Q1
BioSpace
Tue, 04/9/24 - 11:50 am
oncology
clinical trials
Bristol Myers Squibb
Opdivo
Yervoy
liver cancer
Pfizer
DLBCL
Adcetris
Asieris
HSIL
APL-1702
cervical cancer
Novocure
non-small cell lung cancer
Roche
Genentech
Tecentriq
esophageal squamous cell carcinoma
Padcev, Keytruda, and Balversa leave little room for Opdivo in urothelial carcinoma
Clinical Trials Arena
Thu, 03/21/24 - 06:41 pm
bladder cancer
urothelial cancer
Merck
Pfizer
Bristol Myers Squibb
Padcev
Keytruda
Balversa
Opdivo
BMS racks up phase III win in liver cancer targeted by AstraZeneca and Roche
BioSpace
Wed, 03/20/24 - 11:51 am
Bristol Myers Squibb
immuno-oncology
Opdivo
Yervoy
liver cancer
AstraZeneca
Roche
Bristol Myers, overshadowed by ADC rival, wins FDA nod for Opdivo combo in bladder cancer
Fierce Pharma
Fri, 03/8/24 - 11:54 am
Bristol Myers Squibb
Opdivo
FDA
bladder cancer
Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data
Xtalks
Mon, 02/5/24 - 10:17 am
oncology
cancer
Keytruda
Revlimid
Opdivo
Imbruvica
Darzalex
Merck
Bristol Myers Squibb
AbbVie
Janssen
BMS' subcutaneous Opdivo clears first phase 3 trial
Pharmaphorum
Mon, 01/29/24 - 11:06 am
Bristol Myers Squibb
Opdivo
clinical trials
kidney cancer
subcutaneous Opdivo
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer
BioSpace
Fri, 12/8/23 - 10:00 am
Bristol Myers Squibb
Opdivo
Yervoy
colorectal cancer
metastatic colorectal cancer
clinical trials
BMS chases Merck/Seagen with first-line bladder cancer filing
Pharmaphorum
Tue, 12/5/23 - 11:53 pm
Bristol Myers Squibb
Opdivo
bladder cancer
urothelial cancer
Merck
Seagen
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
Mon, 10/23/23 - 05:15 pm
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
Fierce Pharma
Sun, 10/22/23 - 06:06 pm
ESMO
Bristol Myers Squibb
Opdivo
bladder cancer
Padcev
Keytruda
Merck

Pages